Professional Summary
Education & Certifications
- Medical Education: University of California at Irvine School of Medicine (1994) CA
- Board Certification: American Board of Internal Medicine, Medical Oncology (2015)
- Fellowship: Stanford University Hematology and Oncology Fellowship (2000) CA
-
- Residency: University of Michigan Health System Internal Medicine Residency (1997) MI
- Internship: University of Michigan Health System Internal Medicine Residency (1995) MI
Publications
-
Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells
Stockerl-Goldstein, K. E., Reddy, S. A., Horning, S. J., Blume, K. G., Chao, N. J., Hu, W. W., … Negrin, R. S. (2000). Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(5), 506–12. -
T cell antigen receptor vaccines for active therapy of T cell malignancies
Reddy, S. A., Okada, C., Wong, C., Bahler, D., & Levy, R. (2001). T cell antigen receptor vaccines for active therapy of T cell malignancies. Presented at the Conference on Basic and Clinical Relevant Biology of Cutaneous T Cell Lymphoma, NEW YORK,NY,NY,NY,NY,NY,NY: NEW YORK ACAD SCIENCES. -
CD30(+) cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma
Liu, H. L., Hoppe, R. T., Kohler, S., Harvell, J. D., Reddy, S., & Kim, Y. H. (2003). CD30(+) cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 49(6), 1049–58. -
-
Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas
Reddy, S. A., & Levy, R. (2004). Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas. BRITISH JOURNAL OF HAEMATOLOGY, 124(5), 626–28. -
Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study
McCormick, A. A., Reddy, S., Reinl, S. J., Cameron, T. I., Czerwinkski, D. K., Vojdani, F., … Levy, R. (2008). Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 105(29), 10131–36. -
Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab
Morales, A. V., Advani, R., Horwitz, S. M., Riaz, N., Reddy, S., Hoppe, R. T., & Kim, Y. H. (2008). Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 59(6), 953–57. -
Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome
Woo, D. K., Jones, C. R., Vanoli-Storz, M. N., Kohler, S., Reddy, S., Advani, R., … Kim, Y. H. (2009). Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome. ARCHIVES OF DERMATOLOGY, 145(6), 667–74. -
A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders
Duvic, M., Reddy, S. A., Pinter-Brown, L., Korman, N. J., Zic, J., Kennedy, D. A., … Kim, Y. H. (2009). A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders. CLINICAL CANCER RESEARCH, 15(19), 6217–6224. -
Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
Whittaker, S. J., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., … Kim, Y. H. (2010). Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 28(29), 4485–91. -
A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy
Hiniker, S. M., Chen, D. S., Reddy, S., Chang, D. T., Jones, J. C., Mollick, J. A., … Knox, S. J. (2012). A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy. TRANSLATIONAL ONCOLOGY, 5(6), 404–7. -
Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma.
Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., & Chang, A. L. S. (2013). Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. British Journal of Dermatology, 169(3), 673–76. -
Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma
Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., & Chang, A. L. S. (2013). Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. BRITISH JOURNAL OF DERMATOLOGY, 169(3), 673–76. -
Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy.
Chen, F. W., Tseng, D., Reddy, S., Daud, A. I., & Swetter, S. M. (2014). Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy. JAMA Dermatology, 150(11), 1209–12. -
Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy
Chen, F. W., Tseng, D., Reddy, S., Daud, A. I., & Swetter, S. M. (2014). Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy. JAMA DERMATOLOGY, 150(11), 1209–12. -
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., … Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology , 33(32), 3750–58. -
Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma
Kim, E. J., Kim, Y. H., Rook, A. H., Lerner, A., Duvic, M., Reddy, S., … Whittaker, S. (2015). Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. LEUKEMIA & LYMPHOMA, 56(10), 2847–54. -
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., … Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology , 33(32), 3750–58. -
Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases
Li, Y., Pan, W., Connolly, I. D., Reddy, S., Nagpal, S., Quake, S., & Gephart, M. H. (2016). Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases. JOURNAL OF NEURO-ONCOLOGY, 128(1), 93–100. -
A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.
Hiniker, S. M., Reddy, S. A., Maecker, H. T., Subrahmanyam, P. B., Rosenberg-Hasson, Y., Swetter, S. M., … Knox, S. J. (2016). A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. International Journal of Radiation Oncology, Biology, Physics, 96(3), 578–88. -
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., … Cheever, M. A. (2016). PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. NEW ENGLAND JOURNAL OF MEDICINE, 374(26), 2542–52. -
Toward rapid learning in cancer treatment selection: An analytical engine for practice-based clinical data.
Finlayson, S. G., Levy, M., Reddy, S., & Rubin, D. L. (2016). Toward rapid learning in cancer treatment selection: An analytical engine for practice-based clinical data. Journal of Biomedical Informatics, 60, 104–13. -
Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.
Reddy, S. A. (2016). Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting. Critical Reviews in Oncology/Hematology, 106, 99–107. -
Phase I Trial: SABR and Ipilimumab-Letter.
Hiniker, S. M., Reddy, S. A., Swetter, S. M., & Knox, S. J. (2017). Phase I Trial: SABR and Ipilimumab-Letter. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 23(1), 320. -
Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study.
Chang, A. L., Tran, D. C., Cannon, J. G., Li, S., Jeng, M., Patel, R., … Colevas, A. D. (2018). Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study. Journal of the American Academy of Dermatology. -
Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.
Nobashi, T., Baratto, L., Reddy, S. A., Srinivas, S., Toriihara, A., Hatami, N., … Mittra, E. (2019). Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT. Clinical Nuclear Medicine. -
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., … Topalian, S. L. (2019). Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1801896. -
Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up.
Gutkin, P. M., Hiniker, S. M., Swetter, S. M., Reddy, S. A., & Knox, S. J. (2018). Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up. Cureus, 10(12), e3723. -
Management of Immunotherapy-Related Toxicities. Version 1.2019
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., … Scavone, J. L. (2019). Management of Immunotherapy-Related Toxicities. Version 1.2019. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(3), 255–88. -
A phase 1b, open-label, investigator-initiated, proof-of-concept study of pembrolizumab for advanced basal cell carcinomas
Chang, A., Duy Tran, Cannon, J., Li, S., Jeng, M., Rieger, K., … Colevas, D. (2019). A phase 1b, open-label, investigator-initiated, proof-of-concept study of pembrolizumab for advanced basal cell carcinomas. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 81(4), AB8. -
Economic analysis of alternative pembrolizumab and nivolumab dosing strategies at an academic cancer center.
Hall, E. T., Zhang, J., Kim, E.-J., Hwang, G., Bhatia, S., & Reddy, S. A. (2019). Economic analysis of alternative pembrolizumab and nivolumab dosing strategies at an academic cancer center. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.
Amin, A., Milhem, M. M., Long, G. V., Hoimes, C. J., Medina, T. M., Conry, R. M., … Ribas, A. (2019). Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center.
Hall, E., Zhang, J., Kim, E. J., Hwang, G., Chu, G., Bhatia, S., & Reddy, S. (2020). Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center. Cancer Medicine. -
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., … Engh, A. (2020). NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. Journal of the National Comprehensive Cancer Network : JNCCN, 18(3), 230–41. -
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.
Postow, M. A., Knox, S. J., Goldman, D. A., Elhanati, Y., Mavinkurve, V., Wong, P., … Barker, C. A. (2020). A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.
Nakamoto, R., Zaba, L. C., Rosenberg, J., Reddy, S. A., Nobashi, T. W., Davidzon, G., … Franc, B. L. (2020). Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging. -
Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab.
Sodji, Q. H., Gutkin, P. M., Swetter, S. M., Reddy, S. A., Hiniker, S. M., & Knox, S. J. (2020). Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab. Melanoma Management, 7(1), MMT36. -
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., … Levy, R. (2020). Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of Experimental Medicine, 217(9). -
Intracranial Tumor Control Following Immune-Related Adverse Events and Discontinuation of Immunotherapy for Melanoma.
Zhang, M., Rodrigues, A. J., Bhambhvani, H. P., Fatemi, P., Pollom, E. L., Gibbs, I. C., … Li, G. (2020). Intracranial Tumor Control Following Immune-Related Adverse Events and Discontinuation of Immunotherapy for Melanoma. World Neurosurgery. -
"Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma".
Narala, R., Reddy, S. A., & Mruthyunjaya, P. (2020). "Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma". American Journal of Ophthalmology Case Reports, 20, 100891. -
Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., … Franc, B. (2020). Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., … Franc, B. (2020). Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis
Zhu, H., Lee, D., Sarah, W., Galdos, F. X., D'Addabbo, J., Fowler, M. B., … Wu, S. M. (2020). Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis. CIRCULATION RESEARCH. LIPPINCOTT WILLIAMS & WILKINS. -
Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.
Nakamoto, R., Zaba, L. C., Liang, T., Reddy, S. A., Davidzon, G., Aparici, C. M., … Franc, B. L. (2021). Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk.
Velez, G., Nguyen, H. V., Chemudupati, T., Ludwig, C. A., Toral, M., Reddy, S., … Mahajan, V. B. (2021). Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk. Molecular Cancer, 20(1), 39. -
Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.
Waliany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., … Zhu, H. (2021). Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors. JACC. CardioOncology, 3(1), 137–39. -
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., … Topalian, S. L. (2021). Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. Journal for Immunotherapy of Cancer, 9(4). -
Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient.
Hirotsu, K. E., Hua, V., Tran, A. T., Morris, L., Reddy, S. A., Kwong, B. Y., & Zaba, L. C. (2021). Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient. JAAD Case Reports, 13, 144–146. -
Intracranial Response to Combination BRAF and MEK Inhibitor Therapy in Patients with Metastatic Melanoma
Hui, C., Wu, Y. (F., Liu, K., Sandhu, N., Blomain, E., Binkley, M., … Pollom, E. (2021). Intracranial Response to Combination BRAF and MEK Inhibitor Therapy in Patients with Metastatic Melanoma. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., … Ramchandran, K. (2021). Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial.
Zager, J. S., Orloff, M., Ferrucci, P. F., Glazer, E. S., Ejaz, A., Richtig, E., … Ottensmeier, C. (2021). Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
The complexity of carcinosarcoma.
Reddy, S. (1800). The complexity of carcinosarcoma. Oncology (Williston Park, N.Y.), 35(12), 814. -
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
Thompson, J. A., Schneider, B. J., Brahmer, J., Achufusi, A., Armand, P., Berkenstock, M. K., … Hang, L. (2022). Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 20(4), 387–405. -
Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
Zhu, H., Galdos, F. X., Lee, D., Waliany, S., Vivian Huang, Y., Ryan, J., … Wu, S. M. (2022). Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis. Circulation, 101161CIRCULATIONAHA121056730. -
Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020.
Qian, M. F., Betancourt, N. J., Pineda, A., Maloney, N. J., Nguyen, K. A., Reddy, S. A., … Zaba, L. C. (2022). Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020. The Oncologist. -
FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).
Zager, J. S., Orloff, M. M., Ferrucci, P. F., Glazer, E. S., Ejaz, A., Richtig, E., … Ottensmeier, C. (2022). FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma.
Hui, C., Wu, Y. F., Liu, K., Sandhu, N., Blomain, E., Binkley, M. S., … Pollom, E. (2022). Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma. Cureus, 14(11), e31838. -
ESC Cardio-Oncology Guidelines: A Triumph-But Are We Overscreening?
Witteles, R. M., & Reddy, S. A. (2023). ESC Cardio-Oncology Guidelines: A Triumph-But Are We Overscreening? JACC. CardioOncology, 5(1), 133–136. -
Toward the Development of Functional Biomarker Assays: Analysis of Neoadjuvant Intralesional Oncolytic Virus Response in High-Risk Stage II Melanoma
Kirane, A., Lee, D., Ahmad, M. U., Sharma, S., Serasanambati, M., Lowe, M., … Maverakis, E. (2024). Toward the Development of Functional Biomarker Assays: Analysis of Neoadjuvant Intralesional Oncolytic Virus Response in High-Risk Stage II Melanoma. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
-
Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
- Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy
- A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
- Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
- Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
- Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
- Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
- A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors
- Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma
- JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
- Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Practice Locations
Skin Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Skin Cancer Program in Palo Alto
900 Blake Wilbur Drive, 3rd Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereStanford Pigmented Lesion and Melanoma Program at Stanford Cancer Center Palo Alto Palo Alto, CA
Palo Alto, CA
Stanford Pigmented Lesion and Melanoma Program at Stanford Cancer Center Palo Alto
900 Blake Wilbur Drive, 3rd Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereCancer Immunotherapy Program Palo Alto, CA
Palo Alto, CA
Cancer Immunotherapy Program
875 Blake Wilbur Dr
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereOcular and Orbital Oncology Palo Alto, CA
Palo Alto, CA
Ocular and Orbital Oncology
2452 Watson Ct
Palo Alto , CA 94303
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(222 reviews)
I am extremely pleased to have such great attention and care from doctor Reddy and staff everyone is so welcoming and humble to care for your health. The staff are professional and honest and advise you on your personal needs and treatments for the best possible health care.
Dr Reddy is thorough professional and very caring. Sunil’’s expertise is highly appreciated and i recommend him highly.
Thank you for your excellent care.
The Best Stanford Med and Cancer Center have!
Like him as my doctor very much
Dr. Reddy is up front, informative and able to give the information I needed.
Excellent doctor. Compassionate, knowledgeable, communicates well.
Highly recommend.
Thank you for all the support and attention you give to me.
He seems excellent to me.
Really like and appreciate his expertise on my condition. He was 100% there for me and is a true professional. I feel grateful to have Dr. Reddy and his staff supporting me.
Very competent and knowledgeable,. I highly respect his medical judgment.
He’s very knowledgeable and nice
Excellent in every regard
Thorough and clear communicator.
I wrote it in the previous page.
Just adding that all these years that I’ve been seeing Dr Reddy, I’ve been telling my family and friends that I have been lucky to have him as my doctor.
excellent call
Dr. Reddy is positive and helpful. I understand that Merkel Cell is rare and must be treated for at least a year possibly 2 years.
Excellent doctor. I appreciate his wisdom and guidance and gentle manner.
Dr Reddy was easy to understand, and gave good guidance on next steps for my health issues. I appreciate him as a physician that is nice to work with, and makes you feel confident in the health journey.
Outstanding Doctor
I think he is an excellent doctor, he has even taken time to explain to me how cancer works and how radiation works. he has been very good to me as far as I'm concerned. I would gladly recommend him to anyone that I think would need his help.
He was awesome and very nice and clear with his comments.
Very pleasant conversation
Thank you for a good discussion regarding my health concerns and test results.
Very easy to talk with. Very thorough discussion.
He was very helpful
He is a skilled Dr. with a very good reputation.
I have never been disappointed with the medical advice I have gotten at Standard.
He is Excellent. Very Knowledgeable and extremely thorough.
He was very polite and made every effort to be helpful.
Dr. Reddy explains everything very well and I am able to understand them. He answered my questions and gave me the plan forward to treat my cancer.
He is very precise and answered all questions.
Great communicator
Excellent Video Visit. Reviewed my progress. Answered my
questions.
Dr. Reddy explains my health issues in layman’s terms which is very helpful. I’m now able to tell my other doctor what we discussed.
It was an honor and pleasure to have the opportunity to meet Dr. Reddy and the other doctors and caregivers. I got really good advice and felt reassured after the visit.
Outstanding Physician
Excellent staff and doctor
Excellent doctor! Dr. Reddy is very positive, which is very encouraging for the patient. He is also very knowledgeable and explains things to the patient in a helpful manner.
Informed me of what is going on with my case. Told me how they would proceed, what my options are for treatment & his opininion. Answered my questions and some of my concerns.
Dr Reddy and his staff are very good and a pleasure to work with.
Good video visit -- on time, efficient and through.
Next steps defined.
Brillant physician! He saved my live!
Good communication, answered my questions
Dr. Reddy is very knowledgeable and I feel privileged to have
him involved in my treatment.
Dr. Reddy is one of the most positive and upbeat doctors I’ve met in oncology. He truly wants his patients to be well and to heal. He makes recommendations and suggestions on what to do next. He won’t leave any stone unturned, he digs and digs. I don't have anxiety prior to meeting with Dr Reddy or his team. He treats his staff with dignity and respect when he asks them to do something or to f/u on a test result, etc. He has returned my calls after clinic hours which can be late into the evening, following up on his promise “I’ll call you today†. I am thankful for his dedication and hard Work.
Great
Dr. Reddy is an excellent Doctor and I feel fortunate he has accepted me
as a patient.
He listened well to what I had to say. Told me clearly what steps we would follow going forwards. Arranged for us to connect in the future. Overall, an excellent video call.
Superb doctor! I would recommend him to anyone.
Dr. Sunil Reddy is an outstanding oncologist. He listens to the patient and carefully designs treatments to fit the individual. His treatment for me his so far been successful beyond what I could hope for.
Very clear and direct communicator, and has an excellent bedside manner.
Dr Reddy is easy to understand and is interested in my welfare.
Dr. Reddy is easy to communicate with and he remembers my history and issues. I never feel like he is in a hurry. He is thorough as is his nurse, Laura.
He’s an excellent Dr. and I feel privileged to have him.
Dr. Reddy has a great bedside manner as did Rosa Patel, his associate.
Dr. Reddy addressed all my concerns and questions with thoughtfulness and compassion.
He was unrushed, listened carefully, very clear and understandable dialog, very informative, patient and caring. It was a very satisfactory visit.
Dr Reddy is a caring person and keeps in touch with others involved with my care, very efficient and pleasant to talk to.
Veryknowledgeable, compassionate physician.
I greatly appreciated his professionalism, clear explanations and forthright recommendations.
He was thoughtful, direct and listened and responded to me as a person ; not just another patient.
I think Dr Reddy is very serious doctor.
I greatly appreciate his expertise and guidance which is always freely given.
Good. Doctor
Amazing
Dr. Reddy is marvelous and I feel fortunate to have him providing
information and care for me.
I was impressed with him,
Great doctor, and has done wonderful things in treating by medical issue!
I am grateful for Dr Reddy’s time and knowledge. My appointments with him never feel rushed, I’m provided ample opportunity to ask questions and discuss current happenings. Dr Reddy is always solid on my timeline, don’t have to remind him of anything which makes me feel valued and taken care of. It’s a privilege to have a doctor like Dr Reddy — who knows me, cares about my well-being and whom I can trust without hesitation.
He is an excellent Dr.
He was great, compassionate and just what I needed.
Doctor Reddy is a very nice and helpful doctor.
excellant
He is my best doctor.
Very easy visit.
I am grateful for Dr Reddy’s care, composure, and kindness.
Dr Reddy has been very good in explaining issues that pertain to my condition / illness. He is very detailed in responding to my questions and seems very approachable and relaxed. And he has beautiful nurses.
Amazing doctor!
Dr. Reddy is an excellent Doctor and a credit to Stanford.
Wonderful doctor!
Dr. Reddy is a talented, thoughtful, caring physician. I am grateful to be his patient.
I feel very fortunate to have been under the care of Dr Reddy and his caring professional team
Dr. Reddy and his wonderful team have been a big part of my treatment, knowledge of my disease and recovery so I can live a full life. I feel honored to have Dr. Reddy and his team as part of my health care. God bless Dr. Reddy his team and the clinic.
It was a well organized vedio visit which I really enjoyed it and fully satisfied. Thank you
I appreciate Dr. Reddy's professionalism, thoughtful communication, and obvious expertise.
Great dr very informative and thorough
Dr Reddy is excellent. He shows genuine concern for his patients.
Dr. Reddy is the BEST!!!
I have been really please with the care Dr Reddy has provided for me during my health issues.
I feel like he has saved my life.
Well informed and responsive
Just a big thank you to the care I have received
All my questions were answered and testing and treatment were proposed
The choice of personal and Video visit is highly appreciated
Very professional
I like and have faith in Doctor. Am sticking with him.
Wonderful, kind, present seems to remember me. I am appreciative of his devoted attention during our visit. I am able to talk with him, rather than just having to listen to what he says. He listens to me.
I like Dr Reddy because he will listen to your concerns and come up with a solution to make things better for you.
Dr, Reddy is wonderful and I am thankful he is my Doctor.
Very thorough, caring staff.
Thorough but kind and compassionate.
Dr. Reddy is an outstanding oncologist. I am so lucky to have had him as my doctor for the last 5 yrs
Dr. Reddy's advice made it possible for me to get all visible signs of cancer out of my body. I plan to continue to rely on his advice.
BEST
Calm, competent, clear
Time is taken to review current medications, talk about any new symptoms, etc. All is recorded in my file.
I have high regard for Dr. Reddy. He is very knowledgeable and thorough, expresses himself in a clear and understandable way, and in a calming manner. I feel fortunate to have him and his staff looking after my health.
Veryk knowledgable and I feel comfortable having him as my Doctor.
He and his team have been able to provide excellent care and attention to my medical condition.
He is SUPER!
The best!
Wonderful doctor!! Very thorough, helpful.
Okay, Sunil Reddy Is very thorough. He has a way of making me feel completely at ease. I look forward to seeing him next year. I appreciate Dr Reddy.
Great doctor. Personable and caring.
Dr. Reddy is the excellent doctor , very attentive and my husband doesn't have a problem to schedule the appointment when he needs it.
He seemed knowledgeable and helpful. I would like to have seen more of him.
Provides excellent care and easy to communicate with
I truly like his professionalism as a doctor to patient setting. Dr Reddy and his team put your worries at ease, by making sure all questions are answered and treatment is at its best. The call backs and messaging from his office is outstanding.
He is a good doctor
Dr. Reddy is a wonderful and caring Doctor. Stanford is lucky to have
him. His high standards are also demonstrated by his Staff in following his examples.
We feel lucky to have Dr. Sunil Reddy as our Oncologist.
Dr. Reddy has always taken a personal concern in my well-being as his patient.
Excellent and caring physician. Knowledgeable, personable, humble.
Dr Reddy is a top notch, intelligent, kind, personal, communicative dedicated expertise dr!
Good person and good doctor
He is an excellent ‘ compassionate doctor who has given me and my family excellent care over the last 5 years.
He was very thorough and provided a lot of information
Excellent and understandable doctor.
Recommend Stanford to all
good on a video visit.
Thank you and your team for all that you do. People’s life’s are better for the treatments you provide. Let’s hear it for team Reddy. ðŸ‘
They are good, experienced, confidence building individuals.
I am very satisfied with care I have received from Dr.Reddy the past 4 years. I appreciate how he has answered my questions and concerns with compassion and professionalism regarding a worrisome diagnosis.
Dr. Reddy is very connected to the needs and concerns of his patients which makes each visit a positive experience.
Dr. Reddy and his PA offered excellent advice concerning following option after my current surgery.
Dr. Reddy and his team are outstanding!
Dr. Reddy listened & heard my concerns.
Excellent.
Dr. Reddy & his N.P. are very knowledgeable & approachable.
Dr. Reddy & his (PA) (NP) are outstanding when visiting with me.
Feel lucky to have Dr. Reddy as my doctor.
Dr. Reddy is wonderful.
I have recommended this facility and this care provider to many persons.
So far my experience at this facility has been enjoyable, friendly and on time.
Knowledgeable, patient.
Excellent doctor & student doctor.
Dr. Reddy is outstanding - both medically and as a human being.
Dr. Reddy is awesome.
Dr. Reddy and his team are wonderful!
I love Stanford and would recommend it to family and friends.
Dr. Reddy & his whole team are tremendous.
Very positive & informative interaction.
Never received a call back from Dr. Reddy after he reviewed the case. Kaiser indicated he contacted them, but we didn't receive any correspondence from Dr. Reddy & PA.
Entire team is excellent. Check in staff, Dr. Reddy, Dr. Evan Hall, Jaime Reis, NP, Laura Morris, RN.
EVERY question answered w/out feeling rushed.
Sometimes waiting too long. Dr. Reddy kind of quiet, but explained all that was happening.
Good.
Dr. Reddy, Dr. Evan Hall & Laura Morris, RN are phenomenal. They are warm, friendly & caring every single time. Top notch professionals.
Dr. Reddy and his staff are wonderful.
Dr. Reddy and his staff (Laura, Jaime) have always been wonderful and supportive.
Dr. Reddy is a doctor's doctor.
Excellent care team. Great results!
Dr. Reddy is great! Such an excellent care provider.
5. No meds. 6. No follow up.
Was especially impressed where the doctor thanked us for coming 6 hrs. (out of our comfort zone) that he appreciated our confidence in him.
They are very active in the health of the people & also very expert in the care of the patients.
Always recommending my family and friends to Stanford great place and all of you can be very proud of your people you have working for you.
Dr. Reddy is a wonderful doctor.
Incredible doctor and staff!
Dr. Reddy is wonderful!
Good.
Outstanding.
Excellent people.
Dr. Reddy & Laura Morris are AWESOME! #10. Already have.
The whole staff including Dr., nurses & medical staff are all excellent professionals but still very nice & easy to talk with.
We felt Dr. Reddy, and staff knowledgeable respectful, able to teach/explain/answer all our questions. Dr. Reddy and Dr. Swang had a well thought out treatment plan to offer us hope. We left feeling we had gone to the "very best" medical center/doctors, we could have chosen!
Seemed rushed.
Dr. Reddy and Phoung Pham are excellent care providers.
Love my health care staff.
Dr. Sumil Reddy is an incredible doctor. Best ever.
Previously, Dr. Reddy seemed rushed and somewhat dismissive. This time, he was much more attentive and detailed.
Excellent attention.
Dr. Reddy and his staff are excellent!
Great experience with Dr. Reddy, Dr. Mascar, and Jamie Faris.
This was a very good experience a consultation that was not stressful at all.
I would highly recommend Dr. Reddy.
Thanks for excellent service!
Great thank you.
Dr. Reddy is awesome & I feel so blessed to have. He & his staff there for me!
Great doctor.
Dr. Reddy is wonderful - a great care provider.
Extremely pleased.
Dr. Reddy and Laura Morris are beyond fantastic!
Dr. Reddy rocks!!
I have recommended this provider with several people.
I cannot EVEN THINK of a sour note I have only good. I love my time at Stanford!
Excellent.
I have the highest praise for Dr. Reddy. He is personable and friendly, yet very professional. He answers questions well. I have complete confidence in his expertise.
Dr. Reddy was knowledgeable and relayed information in an easily understandable way. He was thorough & presented me with a variety of options. I totally trust his judgment.
I have recommended this care provider several times.
All those extra checks mean I have the best care & the best dr. & nurses - Thank you -
Very thorough, clear & patient w/my questions & concerns.
Dr. Reddy is a great doctor - caring, compassionate, kind and extremely knowledgeable.
Learned a significant amount of information about the medications I am taking.
We are always greeted with a smile and a good word.
I love Dr. Reddy!
The entire team, NP, PA & MD are all the best I could hope for, and I am fortunate to have them.
Dr. Kipp Weis kept was excellent - saw me first. dr. Reddy was outstanding.
I feel he has not informed me well enough as to what's happening, his concerns on explanations. I feel like I'm flying blind!!
I have recommended this provider to several people.
Good.
I have recommended him.
Dr. Reddy has been like a primary care physician. Very good.
Dr. Reddy is outstanding! His care and concern and availability dealing with my stage 4 melanoma problems are a great help.
Dr. Reddy is trying to do everything he can to save my life. I'm so grateful to have him as my dr.
Dr. Reddy is a caring hands on doctor who spends time knowing all issues of my cancer and provides me with excellent personalized service.
Provider seemed perfunctory and no follow-up.
Dr. Reddy and the PA spent an incredible amount of time with me.
Dr. Reddy - excellent doctor.
1 hr. w/me.
Dr. Reddy and David Nguyen spent a TON of time answering all our questions about cancer treatment. Very patient and thorough.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records